Views & Analysis Pandemic boost to decentralised trials is here to stay Due to the pandemic, decentralised trial solutions made the shift from an emerging trend to a crucial element of drug development.
Partner Content Partner Content Making the most of your remaining communications budget pharmaphorum connect's Mark Walmsley describes seven projects to maximise remaining communications budgets.
News In shock move, EU panel rejects Alzheimer's drug Leqembi The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
Sales & Marketing Sponsored How doctors are interacting with content in 10 data trends It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.